MedTrace Logo

ECC5004 DDI Study With Atorvastatin, Rosuvastatin, Digoxin and Midazolam in Healthy Participants

NCT06293742 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2024-07-22

No results posted yet for this study

Summary

This is a Phase 1, open-label, non-randomized, fixed sequence study designed to evaluate the effect of ECC5004 on single dose pharmacokinetics of Atorvastatin, Rosuvastatin, Digoxin and Midazolam in healthy participants.

Conditions

Interventions

DRUG

ECC5004

ECC5004 tablet will be administered orally.

DRUG

Midazolam

Midazolam will be administered orally.

DRUG

Rosuvastatin

Rosuvastatin will be administered orally.

DRUG

Digoxin

Digoxin will be administered orally.

DRUG

Atorvastatin

Atorvastatin will be administered orally.

Sponsors & Collaborators

  • Eccogene

    lead INDUSTRY

Principal Investigators

  • Eccogene · Eccogene Clinical Trials

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-02-08
Primary Completion
2024-04-15
Completion
2024-04-15
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06293742 on ClinicalTrials.gov